High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC study. 2010

Na Zhu, and James S Pankow, and Christie M Ballantyne, and David Couper, and Ron C Hoogeveen, and Mark Pereira, and Bruce B Duncan, and Maria Inês Schmidt
Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Suite 300, Minneapolis, Minnesota 55454, USA. zhuxx210@umn.edu

BACKGROUND Adiponectin, synthesized by adipocytes, has been shown to be a predictor of type 2 diabetes. Adiponectin circulates in plasma as three oligomeric isoforms. High-molecular-weight (HMW) adiponectin is thought to be the most biologically active form of adiponectin in terms of glucose homeostasis. OBJECTIVE Our objective was to investigate whether HMW adiponectin is more strongly associated with incident diabetes than is total adiponectin. METHODS A nested case-cohort study was conducted in a population-based cohort of 9740 middle-aged, initially healthy, white and African-American participants of the Atherosclerosis Risk in Communities (ARIC) study followed for up to 9 yr. Plasma total and HMW adiponectin were measured by ELISA in 550 incident diabetes cases and 540 noncases. RESULTS Overall hazard ratios (95% confidence intervals) for developing diabetes for those in the fourth (vs. the first) quartile of total adiponectin, HMW adiponectin, and the ratio of HMW to total were 0.40 (0.25-0.64), 0.38 (0.23-0.63), and 0.65 (0.42-0.99), respectively, after adjustment for age, sex, ethnicity, study center, parental history of diabetes, hypertension, body mass index, and waist-to-hip ratio and 0.52 (0.32-0.85), 0.51 (0.31-0.86), and 0.77 (0.50-1.20), respectively, after additional adjustment for inflammation score (a score composed of six inflammation markers) and fasting insulin. When further adjusting for baseline fasting glucose, the graded associations were attenuated substantially and lost their gradation. CONCLUSIONS In this community-based sample of U.S. adults, higher total and HMW adiponectin concentrations were similarly associated with a lower incidence of diabetes over 9 yr of follow-up.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001741 Black or African American A person having origins in any of the black racial groups of Africa (https://www.federalregister.gov/documents/1997/10/30/97-28653/revisions-to-the-standards-for-the classification-of-federal-data-on-race-and-ethnicity). In the United States it is used for classification of federal government data on race and ethnicity. Race and ethnicity terms are self-identified social construct and may include terms outdated and offensive in MeSH to assist users who are interested in retrieving comprehensive search results for studies such as in longitudinal studies. African American,African Americans,African-American,Afro-American,Afro-Americans,Black Americans,Blacks,Negroes,African-Americans,Negro,Afro American,Afro Americans,American, African,American, Black,Black American
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012306 Risk The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome. Relative Risk,Relative Risks,Risk, Relative,Risks,Risks, Relative

Related Publications

Na Zhu, and James S Pankow, and Christie M Ballantyne, and David Couper, and Ron C Hoogeveen, and Mark Pereira, and Bruce B Duncan, and Maria Inês Schmidt
March 2007, Diabetic medicine : a journal of the British Diabetic Association,
Na Zhu, and James S Pankow, and Christie M Ballantyne, and David Couper, and Ron C Hoogeveen, and Mark Pereira, and Bruce B Duncan, and Maria Inês Schmidt
September 2008, Annals of internal medicine,
Na Zhu, and James S Pankow, and Christie M Ballantyne, and David Couper, and Ron C Hoogeveen, and Mark Pereira, and Bruce B Duncan, and Maria Inês Schmidt
August 2008, The Journal of clinical endocrinology and metabolism,
Na Zhu, and James S Pankow, and Christie M Ballantyne, and David Couper, and Ron C Hoogeveen, and Mark Pereira, and Bruce B Duncan, and Maria Inês Schmidt
February 2014, Obesity (Silver Spring, Md.),
Na Zhu, and James S Pankow, and Christie M Ballantyne, and David Couper, and Ron C Hoogeveen, and Mark Pereira, and Bruce B Duncan, and Maria Inês Schmidt
October 2006, The Journal of clinical endocrinology and metabolism,
Na Zhu, and James S Pankow, and Christie M Ballantyne, and David Couper, and Ron C Hoogeveen, and Mark Pereira, and Bruce B Duncan, and Maria Inês Schmidt
November 2008, Diabetes research and clinical practice,
Na Zhu, and James S Pankow, and Christie M Ballantyne, and David Couper, and Ron C Hoogeveen, and Mark Pereira, and Bruce B Duncan, and Maria Inês Schmidt
April 2009, Translational research : the journal of laboratory and clinical medicine,
Na Zhu, and James S Pankow, and Christie M Ballantyne, and David Couper, and Ron C Hoogeveen, and Mark Pereira, and Bruce B Duncan, and Maria Inês Schmidt
October 2016, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association,
Na Zhu, and James S Pankow, and Christie M Ballantyne, and David Couper, and Ron C Hoogeveen, and Mark Pereira, and Bruce B Duncan, and Maria Inês Schmidt
February 2012, Diabetes care,
Na Zhu, and James S Pankow, and Christie M Ballantyne, and David Couper, and Ron C Hoogeveen, and Mark Pereira, and Bruce B Duncan, and Maria Inês Schmidt
March 2015, European journal of preventive cardiology,
Copied contents to your clipboard!